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Background: Standard treatment strategies for embryonal central nervous system (CNS) tumors have not yet been
established. We treated these tumors using an original chemoradiation therapy protocol; the clinical outcomes and
toxicities were retrospectively evaluated.
Methods: Twenty-four patients were enrolled including sixteen with medulloblastoma, four with supratentorial
primitive neuroectodermal tumor (sPNET), three with atypical teratoid/rhabdoid tumor, and one with
pineoblastoma. Immediately after diagnosis, all patients underwent surgery initially. They were then categorized as
high- or average-risk groups independent of tumor type/pathogenesis. The average-risk group included patients
who were aged ≥3 years at diagnosis, had non-metastatic disease at diagnosis (M0), and had undergone gross total
resection. Other patients were categorized as the high-risk group; this group received more intensive treatment
than the average-risk group, including high-dose chemotherapy with autologous stem-cell transplantation. All patients
received craniospinal irradiation (CSI). The CSI dose was 23.4 Gy for M0 patients aged ≥5 years, 18 Gy for M0 patients
aged <5 years, and 30–36 Gy for all patients with M + disease. The total dose to the primary tumor bed was 54 Gy.
Results: The median follow-up time was 73.5 (range, 19–118) months. The 5-year progression-free survival (PFS) and
overall survival (OS) rates were 71.1 and 88.9%, respectively in the average-risk group (n = 9) and 66.7 and 71.1%,
respectively in the high-risk group (n = 15). The PFS and OS rates were not significantly different between the
average- and high-risk groups. In patients with medulloblastoma only, these rates were also not significantly
different between the average- and high-risk groups. Three of four patients with sPNET were disease free. The
height standard deviation score (SDS) was significantly decreased at the last assessment relative to that at diagnosis
(P < 0.0001). The latest median height SDS was −1.6 (range, 0.9 to −4.8), and the latest median full-scale intelligence
quotient (FSIQ) score was 86 (range, 59–128). The CSI doses and age at the start of radiation therapy did not influence
clinical outcomes, height SDSs, and FSIQ scores.
Conclusions: Our original protocol for patients with embryonal CNS tumors was feasible and yielded favorable
clinical outcomes.
Keywords: Embryonal central nervous system tumors, Medulloblastoma, Supratentorial primitive neuroectodermal
tumor, Atypical teratoid/rhabdoid tumor, Pineoblastoma, Growth height, Hypothyroidism, Ototoxicity, Cognitive function* Correspondence: k7804140@yokohama-cu.ac.jp
1Department of Radiation Oncology, Yokohama Municipal Citizen’s Hospital, 56
Okazawa-cho, Hodogaya-ku, Yokohama, Kanagawa, Japan
2Department of Radiology, Kanagawa Children’s Medical Center, 2-138-4
Mutsukawa, Minami-ku, Yokohama, Kanagawa, Japan
Full list of author information is available at the end of the article
© 2014 Odagiri et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Odagiri et al. Radiation Oncology 2014, 9:201 Page 2 of 12
http://www.ro-journal.com/content/9/1/201Background
Embryonal central nervous system (CNS) tumors include
medulloblastoma (MB), supratentorial primitive neu-
roectodermal tumor (sPNET), atypical teratoid/rhabdoid
tumor (AT/RT), pineoblastoma and others. As recurrence
with leptomeningeal dissemination is commonly observed,
prophylactic craniospinal irradiation (CSI) is essential for
initial treatment of these diseases. Radiation therapy (RT)
is generally avoided in patients aged <3 years to prevent
the risk of long-term neurocognitive sequelae [1-4].
MB is the most frequent primary solid CNS tumor in
children, accounting for 10–20% of CNS neoplasms and for
approximately 40% of all tumors arising from the posterior
fossa. It can occur in any age group, but the peak incidence
is between the ages of 3 and 7 years. Medulloblastoma pa-
tients are generally categorized as being in average- and
high-risk groups as defined by the Children’s Cancer Study
Group (CCSG). The average-risk group is aged ≥3 years at
diagnosis, have non-metastatic disease at diagnosis (M0),
and have undergone total or nearly total resection. Other
patients are categorized as being in the high-risk group [5].
With average-risk MB, the standard dose of CSI was ap-
proximately 36 Gy until around the year 2000 [6]. Several
clinical trials have been undertaken to reduce the late ad-
verse effects caused by CSI. As a result, reduced-dose CSI
involving a total dose of 23.4 Gy has become the standard
treatment for the average-risk group [7]. Although the opti-
mal treatment strategy in the high-risk group has not yet
been defined, around 36 Gy is considered as the standard
dose for CSI [8]. There is now sufficient evidence that boost
radiation confined to the tumor bed after CSI, at doses up
to 54–55.8 Gy, is adequate for both risk groups [7,9].
sPNET and pineoblastoma are the two most common
subtypes of supratentorial embryonal tumors. The cli-
nical outcomes for sPNET and pineoblastoma have ge-
nerally been inferior to those for MB. In approximately
one third of patients, leptomeningeal dissemination is
apparent at the time of diagnosis or initial recurrence.
Usually, CSI at 36 Gy with a boost of 54–55.8 Gy to the
tumor bed are administered in the same manner as in
high-risk MB patients [10,11].
AT/RT accounts for 1–2% of all pediatric brain tumors;
however, 10–20% occur in patients aged <3 years at
diagnosis. Up to 15–25% of patients show leptomenin-
geal dissemination at diagnosis. The overall survival
(OS) is the worst among all embryonal CNS tumors. In
particular, patients aged <3 years have shorter survival
times than others [12].
Recently, high-risk MB, sPNET, AT/RT, and pineoblas-
toma have been treated using high-dose chemotherapy
(HDC) with autologous stem-cell transplantation (ASCT)
just after induction chemotherapy [9,12,13]. Such aggres-
sive chemotherapy could compensate for the dose reduc-
tion in CSI [14].In the present study, we first categorized all patients
with embryonal CNS tumors as high-risk or average-risk
groups independent of tumor type/pathogenesis refer-
ring to the risk classification which applied for MB, as
defined by the CCSG [5].
Immediately after surgery, the average-risk group re-
ceived conventional chemotherapy, while the high-risk
group received a more intensive chemotherapy regimen
including HDC with ASCT. All M0 patients aged ≥5
and <5 years underwent reduced-dose CSI at doses of
23.4 and 18 Gy, respectively independent of risk group
and tumor type. Therefore, the originality of our proto-
col is that reduced-dose CSI was administered to all pa-
tients with M0 disease, not only to the average-risk MB
patients but also to the high-risk MB, sPNET, AT/RT,
and pineoblastoma patients. The purpose of this study
was to retrospectively evaluate the clinical outcomes
and toxicities.
Methods
Patients and risk classification
Between March 2003 and January 2011, 26 consecutive
patients with newly diagnosed embryonal CNS tumors
were treated in our institution. Two patients were not able
to undergo the initial standard treatment including RT. In
one patient, CSI was cancelled after the delivery of 6 Gy
because of respiratory insufficiency caused by pulmonary
hypertension. The other patient could not undergo CSI
because of intractable epilepsy. The remaining 24 patients
were investigated in this study; their medical records were
retrospectively reviewed. This retrospective study was
performed according to the guidelines of the Kanagawa
Children’s Medical Center Ethical Committee. All patients
underwent magnetic resonance imaging (MRI) of the
brain and whole spine and cerebrospinal fluid exami-
nation. Immediately after diagnosis, all patients under-
went surgery initially. The extent of surgical resection of
the primary tumor was defined as gross tumor resection
(GTR), or non-GTR based on review of the postopera-
tive MRI and the surgeon’s intraoperative assessment.
We categorized all patients with embryonal CNS tumors
as high-risk or average-risk groups referring to the risk
classification which applied for MB as defined by the
CCSG [5]. The average-risk group included patients with
all of the following characteristics: were aged ≥3 years at
diagnosis; had M0 disease; and underwent GTR. Other
patients were categorized as being in the high-risk group.
Treatment after surgery
The treatment protocol is shown in Figure 1. All patients
in both the average- and high-risk groups received 4–6
cycles of chemotherapy including vincristine (1.5 mg/m2,
day 1), etoposide (100 mg/m2, days 1–5), cisplatin
(20 mg/m2, days 1–5), and cyclophosphamide (1.2 g/m2,
Figure 1 Schema of the chemoradiation therapy protocol. ASCT = autologous stem-cell transplantation; CSI = craniospinal irradiation;
GTR = gross total resection; HDC = high-dose chemotherapy; VVCC = vincristine (1.5 mg/m2, day 1), etoposide (100 mg/m2, days 1–5), cisplatin
(20 mg/m2, days 1–5), and cyclophosphamide (1.2 g/m2, days 1–2); y = years.
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administered after 1 or 2 cycles of VVCC and then the
remaining 2–5 cycles were given. In contrast, for the
high-risk group, RT was undertaken after all courses of
chemotherapy had been completed. In addition, for pa-
tients in the high-risk group, HDC with ASCT was ad-
ministered after VVCC. HDC consisted of a total dose
of 800 mg/m2 of TEPA and a total dose of 280 mg/m2 of
melphalan on days −12, −11, −5 and −4. All patients
aged <3 years received maintenance chemotherapy in-
cluding cyclophosphamide (250 mg/m2, days 1–5) and
topotecan (0.75 mg/m2, days 1–5) after the chemother-
apy mentioned above until they were 3 years old. The
chemotherapy protocols were modified in a few pa-
tients. When disease recurrence or progression oc-
curred, salvage chemotherapy was performed.
Treatment planning for RT was performed using an
X-ray simulator until a CT-based planning system was
introduced in 2006. All patients were irradiated using a
linear accelerator based photon beam. A 6-megavolt
(MV) beam was used for CSI and 6- or 10-MV beams
were used for the radiation boost at the primary site.
The daily fraction size for CSI was mainly 1.8 Gy. Four
patients received CSI in 1.5 Gy/fraction and one patient
received CSI in 1.7 Gy/fraction. In all patients, the daily
fraction size for the boost was 1.8 Gy. Five fractions
were given per week. CSI was administered to all pa-
tients. It was performed in the supine position using
parallel-opposed lateral cranial fields that abutted a pos-
terior spinal field. Two types of junctions were used,
termed the ‘low cranial-spinal junction’ and the ‘high
cranial-spinal junction’. These two junctions were chan-
ged daily. The former was set just above the shoulders
and the latter was set 2 cm above the former junction.The lower border of the spinal field was set at the S3–S4
junction.
As shown in Figure 1, the total CSI dose for M0 patients
aged ≥5 years at the start of RT was 23.4 Gy, and for those
aged <5 years it was 18 Gy. The total dose for patients
with metastasis (M+; M1–3) was 30–36 Gy. A boost dose
of 54–55.8 Gy was delivered to the primary tumor bed
with a limited margin of 1–2 cm. It is well known that RT
involving the CNS can cause severe neurological mor-
bidity (i.e. a reduction in the intelligence quotient (IQ),
cognitive deficits, and neuroendocrine dysfunctions) in
children younger than 3 years [1-4]. Therefore, if pa-
tients were aged <3 years at diagnosis, RT was usually
postponed until they had turned 3 years, as long as dis-
ease was controlled by the chemotherapy mentioned
above.
Statistical analysis
Progression-free survival (PFS) and OS rates were calcu-
lated according to the Kaplan–Meier method. PFS
reflected the interval between diagnosis and clinical and/
or radiological progression. OS was the interval between
diagnosis and death. Comparisons between survival
curves were made using the log-rank test. Statistical sig-
nificance was accepted for P-values <0.05.
Results
Patient demographics
Patient demographics and outcomes are shown in Tables 1
and 2. Of the 24 eligible patients, 16 were male and eight
were female. Median age at diagnosis was 5.7 (range,
0.3–16.0) years. There were 16 MBs, four sPNETs, three
AT/RTs, and one pineoblastoma. Nine and 15 patients
were classified as being in average- and high-risk groups.
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patients with MB patients, while the high-risk group con-
sisted of patients with a variety of diseases. In 10 patients
aged <3 years at diagnosis, four received RT before 3 years
because their treatment had failed to control the disease.
Treatment outcomes
The median follow-up time was 73.5 (range, 19–118)
months from diagnosis and 57.5 (range, 5–103) months
from the start of RT. In the average-risk group (n = 9),
the 5-year PFS and OS rates were 71.1 and 88.9%, re-
spectively. In the high-risk group (n = 15), the 5-year
PFS and OS rates were 66.7 and 71.1%, respectively. The
PFS and OS rates did not differ significantly between the
average- and high-risk groups (Figure 2). If limited to
MB patients, in the average-risk group (n = 9) the 5-year
PFS and OS rates were 71.1 and 88.9%, respectively, and
in the high-risk group (n = 7) the 5-year PFS and OS
rates were 85.7 and 83.3%, respectively. For MB patients,
the PFS and OS rates were not significantly different be-
tween the average- and high-risk groups (Figure 3).
As shown in Table 2, none of the patients with sPNET
had M + disease. One patient died of local failure, whereas
the remaining three patients were disease free until the
last assessment. In three patients with AT/RT, two had
M3 disease and died of leptomeningeal dissemination.
The remaining M0 patient remained disease free. One pa-
tient with pineoblastoma had M3 disease and died of
leptomeningeal dissemination.
Between patients who received CSI at doses of 18 Gy
(n = 8) and 23.4 Gy (n = 10), no significant difference
was found in the 5-year PFS rate (75.0 vs. 75.0%; P =
0.73) or the OS rate (75.0 vs. 90.0%; P = 0.35). There was
no treatment-related death.
Growth height
In 20 of the 24 patients, continuous growth charts were
available at least ≥2 years after initial diagnosis. The
height of these 20 patients was evaluated using a stand-
ard deviation score (SDS) from the age-matched mean
value in the normal Japanese population [15]. The me-
dian age at the latest assessment was 11.5 (range, 4–22)
years. The median time between initial assessment at
diagnosis and the latest assessment was 71.5 (range, 24–
109) months. The data for each patient is detailed in
Tables 1 and 2. Figure 4 shows the differences in the ini-
tial and latest height SDS. The median latest height SDS
was −1.6 (range, 0.9 to −4.8). There were seven patients
with a SDS < − 2. The latest height SDS was significantly
decreased relative to the initial height SDS (P < 0.0001).
The median loss of height SDS was 1.3 (range, 0.1–3.8).
The 20 patients included four who failed to achieve
disease control (Patients 2, 5, 14, and 21, as shown by
the dotted lines in Figure 4). Three of these four patientshad a latest height SDS < − 2. When these four patients
were eliminated, the median latest height SDS was −0.9.
The doses of CSI (>18 Gy vs. ≤18 Gy) and age at the
start of RT (≥5 years vs. <5 years) did not influence the
latest height SDS or the loss of height SDS.
Three patients received growth hormone replacement
therapy.
Hypothyroidism
Direct irradiation of the thyroid could cause primary
hypothyroidism. This is defined as low free thyroxine
(T4) and elevated thyroid-stimulating hormone (TSH)
levels. The subclinical hypothyroidism was defined as a
normal free T4 level but with a high TSH level. In
addition, the damage to the hypothalamic-pituitary axis
could also cause secondary hypothyroidism defined as
low free T4 and TSH levels.
The levels of T4 and TSH were assessed in 15 patients
and the data for each patient is presented in Tables 1 and 2.
Nine patients (60%) developed subclinical hypothyroidism
and three of these received thyroid hormone replacement
therapy (Patients 14, 18, and 22). Patient 15 developed sec-
ondary hypothyroidism immediately after surgery. Neither
age at the start of RT (≥5 years vs. <5 years) nor CSI dose
(>18 Gy vs. ≤18 Gy) affected thyroid function.
We retrospectively assessed the radiation doses to the
thyroid gland in 10 patients whose CT planning data were
available. Mean doses to the thyroid gland were 11.6–
24.7 Gy (median, 18.5 Gy). Subclinical hypothyroidism
was observed in two patients (Patients 1 and 19) who re-
ceived CSI at a dose of only 18 Gy and their estimated
mean doses to the thyroid gland were 11.6 and 11.8 Gy.
Posterior spinal fields for CSI using a high cranial-spinal
junction usually included the whole volume of the thyroid
gland; whereas, using a low cranial-spinal junction the
thyroid volumes varied among individual cases. However,
even when using a low cranial-spinal junction, there were
no cases where the posterior spinal field could completely
exclude the thyroid gland.
Ototoxicity
We used the Brock criteria, which are designed to evalu-
ate cisplatin-related ototoxicity, to analyze hearing status
[16]. Brock grade 0 is <40 dB at all frequencies. Grades
1, 2, 3, and 4 are ≥40 dB at 8000, >4000, 2000, and
1000 Hz, respectively. Audiograms were available for 14
of the 24 patients and the data for each patient is de-
tailed in Tables 1 and 2. Two patients had Brock grade 1
ototoxicity, five had grade 2, and two had grade 4. Seven
patients (50%) suffered hearing loss of Brock grade ≥2,
which often required audiological intervention [17,18].
Of note, hearing loss of Brock grade 2 occurred in Pa-
tient 22 even with a supratentorial tumor; the cumula-
tive cochlea RT dose was estimated as being the same as






































1 F 3.5 3.3 18 54 39 – 6.8 NED −1.1 −2.2 Subclinical NE NE 71
2 M 4.9 5.0 23 54 33 LR 7.7 DOD −1.5 −3.5 NE 4 NE NE
3 M 6.7 6.9 26 54.3 76 – 13.0 NED +1.3 +0.4 – 1 98 59
4 M 7.1 7.3 23 54 94 – 14.9 NED −1.8 −2.5 Subclinical 0 112 110
5 M 7.2 7.3 23 54 98 LF 15.3 AWD −0.5 −2.6 Subclinical 2 135 128
6 M 9.4 9.6 23 54 34 – 12.3 NED +1.0 +0.1 NE 2 NE NE
7 M 10.2 10.4 23 54 48 – 14.2 NED +1.2 −0.2 – 1 81 82
8 F 12.8 12.9 23 55.8 94 – 20.6 NED +1.0 +0.2 NE 2 NE NE
9 F 16.0 16.3 23 54 79 – 22.6 NED +1.0 +0.9 Subclinical NE NE NE
Abbreviations: AWD alive with disease, CSI craniospinal irradiation, DOD death of disease, FSIQ full-scale intelligence quotient; LF local failure; LR leptomeningeal recurrence; NE not evaluated, NED no evidence of
















Table 2 Clinical and treatment-related information for patients with high-risk em ryonal central nervous system tumors































10 M 1.9 I M0 G 2.3 18 54 Yes – PD†
11 M 2.7 I M0 non TR 3.3 18 50.4 Yes – CR
12 M 6.3 I M1 G 6.4 31 54 No – CR
13 F 8.1 I M3 G 8.8 36 54 Yes – CR
14 F 10.2 I M0 non TR 10.9 23 55.8 Yes – PR‡
15 M 10.3 I M0 non TR 11.0 23 54 Yes – CR
16 M 11.8 I M1 G 13.5 23 54 Yes – CR
sPNET
17 M 2.3 S M0 G 3.0 18 54 Yes CT, ICE PD†
18 M 2.4 S M0 G 3.3 18 54 Yes CT CR
19 F 2.4 S M0 G 3.4 18 54 Yes CT CR
20 F 2.5 S M0 Non TR 3.8 18 54 No CT CR
AT/RT
21 M 0.3 I M3 G 1.5 30 51 Yes – CR
22 F 1.3 S M0 Non TR 2.6 18 54 Yes IFNß CR
23 M 2.8 I M3 Non TR 3.3 31 39.6* Yes – PR§
Pineoblastoma

























































28 LR 4.3 DOD NE NE NE 0 NE NE
109 – 11.8 NED −0.3 −1.8 – 0 NE 95
92 – 13.9 NED 0 −1.5 Subclinical 0 88 86
23 – 10.0 NED 0 −0.7 NE 0 NE 96
109 – 19.3 SD +0.5 −1.6 Subclinical 4 101 82
50 – 14.4 NED −2.4 −4.1 Secondary 0 NE 79
83 – 19.8 NED +0.4 −0.7 – 0 102 NE
sPNET
28 LF 4.6 DOD NE NE NE NE 94 NE
92 – 10.1 NED −0.5 −1.9 Subclinical 0 128 107
29 – 4.8 NED +1.1 −0.1 Subclinical NE 86 NE
66 – 8.0 NED −0.9 −2.4 – NE 72 77
AT/RT
71 LR 6.3 DOD −1.0 −4.8 NE 2 NE NE
118 11.2 NED −0.4 −1.1 Subclinical 2 75 62
46 LR 6.7 DOD NE NE NE 0 102 88
Pineoblastoma
19 LR 2.8 DOD NE NE NE NE NE NE
Abbreviations: ASCT autologous stem-cell transplantation, AT/RT atypical teratoid/rhabdoid tumor, CR complete response, CSI craniospinal irradiation, CT cyclophosphamide and topotecan, DOD death of disease,
FSIQ full-scale intelligence, GTR gross total resection, HDC high-dose chemotherapy, I infratentorial, ICE ifosfamide, carboplatin and etoposide, IFN interferon, LF local failure, LR leptomeningeal recurrence, MTX methotrexate,
NE not evaluated, NED no evidence of disease, PD progression disease, PR Partial response, RT radiation therapy, S supratentorial, SD stable disease, SDS standard deviation score, sPNET supratentorial primitive
ectodermal tumor





















Figure 2 Progression-free survival (A) and overall survival (B) of




Figure 3 Progression-free survival (A) and overall survival (B) of
patients with medulloblastoma. MB = medulloblastoma.
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vs. <5 years) did not influence Brock grades ≤1 or ≥2.
Patients 5 and 14 exhibited hearing loss of Brock
grades 2 and 4, respectively, just after surgery, because
their tumors were located close to the auditory nerve.
Cognitive functions
We used three different types of IQ test, which in-
cluded the Wechsler Intelligence Scale for Children-
III, the Tanaka-Binet Intelligence Scale, and the Kyoto
Scale of Psychological Development 2001. Appropriate
tests were used dependent on patient age.
IQ tests were performed after RT on 17 of the 24 pa-
tients. Ten of the 17 patients had multiple/repeated IQ
tests at least twice during follow-up. The data for each
patient is presented in Tables 1 and 2. The median time
between the initial and latest IQ tests was 31 (range, 5–
75) months. The differences in these scores were signifi-
cant and in the range of 5 to −39 (median, −10; P =
0.0195) (Figure 5). The median latest full-scale IQ(FSIQ) score was 86 (range, 59–128). In 13 of the 17
patients, these scores were <100. Patients 3 and 22 had
a FSIQ <70 at the last assessment, which represented
severe mental retardation. Neither the age at the start
of RT (≥5 years vs. <5 years) nor the primary tumor
site (supra- or infra-tentorial) nor the CSI dose
(>18 Gy vs. ≤18 Gy) influenced the FSIQ score.
All of the 18 patients who were disease free until the
last assessment attended normal school. However, six
of the 18 patients had learning disabilities.
Miscellaneous findings
Patient 2 developed a bilateral cataract at 2 years after
RT, but surgery has not yet been required. Patient 14 de-
veloped obesity and hyperlipidemia. She was suspected
as having hypothalamic obesity. Patient 20 was sus-
pected of precocious puberty. Patient 23 developed
Moyamoya disease at 2 years after RT. He had encepha-
loduroarteriosynangiosis; however, he developed right
hemiparesis caused by cerebral infarction after surgery.
Figure 4 Differences in height standard deviation score (SDS)



















Figure 5 Differences in the full-scale intelligence quotient
(FSIQ) at diagnosis and at the last assessment.
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patients investigated in this study.
Discussion
In the present study, we used a reduced-dose (18 or
23.4 Gy) CSI protocol for the treatment of all embryonal
CNS tumor patients with M0 disease. Generally, this
protocol has been applied for limited to average-risk MB
patients. For the treatment of high-risk M0 patients, we
administered aggressive chemotherapy to compensate for
the reduced-dose CSI treatment. As a result, the PFS and
OS rates were not significantly different between the
average- and high-risk groups. For patients with high-risk
MB, studies during the 1990s typically showed a 5-year
PFS of 40–50% following CSI at approximately 36 Gy and
chemotherapy [6,19]. In the present study, the treatment
with reduced-dose CSI for the high-risk MB patients re-
sulted in 5-year PFS and OS rates of 85.7 and 83.3%, re-
spectively; these rates did not differ significantly from
those for average-risk MB patients. In addition, several
studies reported that sPNET has a poorer prognosis than
high-risk MB [20,21]. In the case of sPNET, all four pa-
tients had M0 disease and three of them remained disease
free. These results are promising, although the patient co-
hort was small and requires further follow-up.
Some data have previously been reported regarding
the efficacy of CSI at a dose of 18 Gy instead of 23.4 Gy
for younger patients [22,23]. In our study, all M0 pa-
tients aged <5 years received reduced-dose CSI (18 Gy)
independent of tumor type. There were no differences in
the 5-year OS and PFS rates between patient groups
after CSI at doses of 18 and 23.4 Gy. In particular, four
sPNET and one AT/RT patient with M0 disease received
CSI at 18 Gy, and four of these patients remained dis-
ease free. It is possible that CSI at 18 Gy may be feasible
and yield favorable clinical outcomes for young age
groups. In addition, CSI at this dose may reduce adverse
effects in young patients, as discussed later. Moreover, it
should be established in further clinical trials if a CSI
dose of 18 Gy would also be sufficient for older patients.
The current Children’s Oncology Group study is testing
the efficacy of CSI (18 Gy) in the treatment of average-
risk MB patients aged 3–8 years.
In AT/RT, leptomeningeal dissemination is often ob-
served and the outcome is worse than that for other em-
bryonal tumors. According to recent estimates, the
median OS is in the range of 17–48 months [24-26]. In
our study, two of three patients with AT/RT had M3 dis-
ease and died despite aggressive therapies including
HDC with ASCT and RT. Our protocol was not effective
in the treatment of AT/RT with M3 disease, and further
consideration of treatment strategy is required.
The dilemma regarding the treatment of AT/RT is as
follows. Many patients are younger than 3 years at
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sis [12]. However, it is difficult to decide whether RT
should be administered to patients in this age range
who are at risk of serious late adverse effects. Recent
studies have reported that RT might be more effective
than chemotherapy as an adjuvant treatment, even for pa-
tients younger than 3 years [26,28]. For example, Chi et al.
[29] have shown that the combination of intrathecal
chemotherapy with RT delivered exclusively to the tumor
bed may be a potentially effective strategy for disease con-
trol in these younger patients. In our study, younger pa-
tients with M3 disease were the most difficult to cure.
Whether or not this new strategy is also effective for this
patient group has not yet been clarified; novel clinical tri-
als might be worthwhile.
There have been many studies regarding height impair-
ment in patients with embryonal CNS tumors treated with
CSI [30-32]. Height impairment in these patients is attrib-
uted to a combination of growth hormone deficiency and
radiation osteitis of the vertebral column. Adan et al. [33]
reported that the final height SDSs in patients who
received CSI at doses of 32–36 Gy ranged from −2.4
to −1.6; in addition, height impairment in young patients
was found to be severe. Kiltie et al. [34] reported that final
height SDSs in patients with MB aged < 3 years who re-
ceived CSI at 27–30 Gy was −4.2. In our study, the me-
dian height SDS at the last assessment was −1.6; in
particular, that of younger patients who were < 5 years old
was −1.9. This value was less serious than those reported
in the previous studies mentioned above. The possible
reasons of our favorable results were that our younger M0
patients received lower CSI doses (18 Gy). Brownstein
et al. [32] reported that final height and loss of height
SDSs were negatively associated with CSI dose (<20 vs.
≥20 Gy; P < 0.001). Xu et al. [35] reported that patients
who received CSI at 18 Gy were significantly taller than
those who received CSI at 23–39 Gy. Thus, CSI at 18 Gy
in young patients may have beneficial effects regarding
height. It will be necessary to continue long-term follow-
up because most of our patients had not reached their
final height at the last assessment.
Hypothyroidism is a well-documented common late
effect associated with CSI. In addition, hypothyroidism
is more common in children who received chemother-
apy and CSI [36,37]. Moreover, survivors of pediatric
hematopoietic stem cell transplantation are at increased
risk of thyroid dysfunction, after total body irradiation at
a dose of >7.5 Gy [38]. In our study, hypothyroidism oc-
curred even in two patients who had received CSI at
18 Gy (Patients 1 and 19); according to retrospective as-
sessment of the CT planning data, the mean dose to the
thyroid gland was around 12 Gy. It is important to take
care to reduce the dose to the thyroid gland by means of
patient positioning and treatment planning; for example,it could be effective to set the cranial-spinal junction as
low as possible.
It has been reported that loss of high-frequency sensori-
neural hearing is induced in children by both cisplatin and
radiation [17,39,40]. In RT-induced ototoxicity, the seve-
rity of hearing loss is related to the dose to the cochlea.
Hua et al. [40] and Merchant et al. [18] suggested that the
mean cochlear dose should be less than 35 and 32 Gy, re-
spectively. In our study, 50% of patients suffered hearing
loss of Brock grade ≥2. Of note, we found that a patient
with supratentorial tumor exhibited hearing loss, while
the cumulative cochlea RT dose was as low as the CSI
dose (18 Gy) (Patient 22). Taken together, the threshold
dose has not been established in pediatric patients. In any
case, the dose to the cochlea should be reduced as much
as possible. New RT modalities (i.e., intensity-modulated
RT and proton therapy) may avoid the adverse radiation
effects on the thyroid gland and on the cochlea.
Cognitive dysfunction is common in patients treated
with cranial RT. Several previous studies have shown
that young age is the most prominent risk factor, and
that radiation dose can also be used to predict a decline
in the IQ score [41,42]. In our study, while the latest
FSIQ was lower than 100 in many patients (76.5%), nei-
ther the age at the start of RT nor the primary tumor
site influenced the FSIQ score. These discrepancies may
have occurred as a result of the fact that the younger
M0 patients (<5 years at the start of RT) in our study re-
ceived lower CSI doses (18 Gy) than those given in pre-
vious studies. In addition, all survivors have attended
normal school. Our data suggested that reduced-dose
CSI for young children may have beneficial effects re-
garding cognitive functions.
Conclusions
In conclusion, our protocol for patients with embryonal
CNS tumors was feasible and yielded favorable clinical
outcomes. The PFS and OS rates were not significantly
different between the average- and high-risk groups, not
only in the case of MB but also other embryonal CNS
tumors. While M0 patients aged <5 years received reduced-
dose CSI at 18 Gy, their treatment outcomes, growth
heights, and cognitive functions were the same as those
for other patients. It is possible that CSI at 18 Gy may be
feasible and yield favorable clinical outcomes for young
age groups. Although there were no life-threatening or
disabling late toxicities, several adverse effects that af-
fected quality of life were observed. Close follow-up and
appropriate managements will be essential for all patients
with embryonal CNS tumors.
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